"Stem Cells Market Will Reach $7.3 Billion in 2014," Visiongain Report Predicts
A new report by visiongain predicts that the overall world market for stem cell technologies in medicine will reach $7.3 billion for 2014.
London, United Kingdom, May 26, 2012 --(PR.com)-- That market will be stimulated by new treatments and increasing use of related products in drug development. Those findings appear in Stem Cell Technologies: World Market Outlook 2012-2022, published in May 2012. Visiongain is a business information provider based in London, UK.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants. Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry. Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
That new report provides revenue forecasts to 2022 at world market and submarket level. The work profiles 187 organisations and investigates prospects of the industry and market.
In addition to forecasting the overall world market for the topic, the analysis predicts revenue trends for submarkets:
• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries – adjunct technologies.
The investigation contains discussions of R&D activities, commercial news, research interviews with external authorities and discussions of work on stem cells in leading countries. It analyses the US, the UK, other prominent European countries, Israel, Japan, India, China and South Korea.
Stem Cell Technologies: World Market Outlook 2012-2022 adds to visiongain’s range of analytical reports on emerging industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Stem Cell Technologies: World Market Outlook 2012-2022, please visit: http://www.visiongain.com/Report/826/Stem-Cell-Technologies-World-Market-Outlook-2012-2022
For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Visiongain forecasts that the stem cells market will expand rapidly from 2012 to 2022, achieving multi-billion-dollar revenues worldwide. More than 200 companies operate in that field. The next ten years will result in many new medical products and uses for stem cells. The period to 2022 will establish the foundations of a therapeutic revolution, the report concludes.
Haematopoietic stem cell transplantation is an established treatment for blood cancers. Revenues from transplants of bone marrow, peripheral blood and umbilical cord blood form much of the market in 2012. Banking of umbilical cord blood (other stem cell-containing blood units) and culturing and processing of stem cells for laboratory work are the other established business areas in 2012. That commercial activity is only the start, the report argues, with stem cell technologies poised for important advances by 2020.
Dr James Evans, a pharmaceutical industry analyst in visiongain, explains: “Stem cell technologies have been hyped for a long time, but it’s only now that we’re going to see the first approved products, treatments based on mesenchymal stem cells or improvements to stem cell transplants. Stem cell-based innovations are likely in the treatment of vascular diseases, autoimmune diseases, diabetes, dry AMD and other serious disorders. Some of these breakthroughs will be a commercial reality by 2022.
“The use of stem cells in laboratory assays for drug development is a strong opportunity for the biotechnology industry. Stem cells offer an improved way to model diseases in vitro, identify candidate drugs and perform toxicity testing and other assays. With drug development costs and failures such a concern for the pharmaceutical industry, that segment will be important to the overall stem cells market, representing around a third of its revenues by 2022, our study predicts.”
That new report provides revenue forecasts to 2022 at world market and submarket level. The work profiles 187 organisations and investigates prospects of the industry and market.
In addition to forecasting the overall world market for the topic, the analysis predicts revenue trends for submarkets:
• Stem cell therapies
• Stem cell banks (e.g., cord blood banking)
• Ancillaries – adjunct technologies.
The investigation contains discussions of R&D activities, commercial news, research interviews with external authorities and discussions of work on stem cells in leading countries. It analyses the US, the UK, other prominent European countries, Israel, Japan, India, China and South Korea.
Stem Cell Technologies: World Market Outlook 2012-2022 adds to visiongain’s range of analytical reports on emerging industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Stem Cell Technologies: World Market Outlook 2012-2022, please visit: http://www.visiongain.com/Report/826/Stem-Cell-Technologies-World-Market-Outlook-2012-2022
For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories